BR0212298A - Composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico - Google Patents

Composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico

Info

Publication number
BR0212298A
BR0212298A BR0212298-7A BR0212298A BR0212298A BR 0212298 A BR0212298 A BR 0212298A BR 0212298 A BR0212298 A BR 0212298A BR 0212298 A BR0212298 A BR 0212298A
Authority
BR
Brazil
Prior art keywords
aminoamide
gabapentin
analog
pharmaceutical composition
alpha
Prior art date
Application number
BR0212298-7A
Other languages
English (en)
Other versions
BRPI0212298B1 (pt
BRPI0212298B8 (pt
Inventor
Patricia Salvati
Orietta Veneroni
Roberto Maj
Ruggero Fariello
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of BR0212298A publication Critical patent/BR0212298A/pt
Publication of BRPI0212298B1 publication Critical patent/BRPI0212298B1/pt
Publication of BRPI0212298B8 publication Critical patent/BRPI0212298B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"COMPOSIçãO FARMACêUTICA COMPREENDENDO GABAPENTINA OU UM ANáLOGO DA MESMA E <244>-AMINOAMIDA E SEU USO ANALGéSICO". A invenção revela uma composição farmacêutica que compreende gabapentina ou um análogo da mesma (pregabalina ou tiagabina) e uma <244>-aminoamida e seu uso como analgésico. Um efeito sinergético das respectivas atividades analgésicas foi observado sem aumento concomitante dos efeitos colaterais.
BRPI0212298A 2001-09-03 2002-08-09 composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico BRPI0212298B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01121069 2001-09-03
PCT/EP2002/008910 WO2003020273A2 (en) 2001-09-03 2002-08-09 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use

Publications (3)

Publication Number Publication Date
BR0212298A true BR0212298A (pt) 2004-09-14
BRPI0212298B1 BRPI0212298B1 (pt) 2015-11-03
BRPI0212298B8 BRPI0212298B8 (pt) 2021-05-25

Family

ID=8178510

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212298A BRPI0212298B8 (pt) 2001-09-03 2002-08-09 composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico

Country Status (21)

Country Link
US (2) US8084447B2 (pt)
EP (1) EP1423168B1 (pt)
JP (1) JP4350508B2 (pt)
KR (1) KR100890875B1 (pt)
CN (1) CN1274306C (pt)
AT (1) ATE317280T1 (pt)
AU (1) AU2002333374B2 (pt)
BR (1) BRPI0212298B8 (pt)
CA (1) CA2459470C (pt)
DE (1) DE60209152T2 (pt)
DK (1) DK1423168T3 (pt)
ES (1) ES2253579T3 (pt)
HK (1) HK1070305A1 (pt)
IL (2) IL160523A0 (pt)
MX (1) MXPA04002009A (pt)
NO (1) NO331298B1 (pt)
NZ (1) NZ531586A (pt)
PT (1) PT1423168E (pt)
RU (1) RU2295337C2 (pt)
SI (1) SI1423168T1 (pt)
WO (1) WO2003020273A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP1169060B1 (en) 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1423168B1 (en) 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
JP2006515327A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
ES2339021T3 (es) * 2003-08-25 2010-05-14 Newron Pharmaceuticals S.P.A. Derivados de alfa-aminoamida utiles como agentes antiinflamatorios.
EP1533302A1 (en) * 2003-11-21 2005-05-25 Newron Pharmaceuticals S.p.A. Histidine derivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
CA2604624A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid
CN100410242C (zh) * 2005-06-23 2008-08-13 江苏恩华药业股份有限公司 普瑞巴林中间体及其制备方法
KR20070087596A (ko) 2005-09-19 2007-08-28 테바 파마슈티컬 인더스트리즈 리미티드 (ｓ)-(+)-3-(아미노메틸)-5-메틸헥산산의 비대칭 합성
EP1798236A1 (en) * 2005-12-13 2007-06-20 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
DK2474521T3 (en) * 2006-06-19 2016-10-31 Newron Pharm Spa High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
DK2155663T3 (en) 2007-06-15 2018-01-22 Newron Pharm Spa SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS
BRPI0820657A2 (pt) 2007-12-11 2015-06-16 Newron Pharm Spa Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza
WO2010099200A1 (en) 2009-02-24 2010-09-02 Nektar Therapeutics Oligomer-amino acid conjugates
AU2011246707B2 (en) 2010-04-27 2014-11-20 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their R-enantiomers
KR20210061357A (ko) * 2018-09-04 2021-05-27 미네르바 뉴로사이언스즈, 인크. 통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3658967A (en) * 1966-06-23 1972-04-25 Ici Ltd Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
CH480308A (de) * 1966-08-11 1969-10-31 Ciba Geigy Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3050800C2 (pt) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
DK153787C (da) * 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
ZA805476B (en) 1979-09-26 1981-11-25 Robins Co Inc A H 2-amino-3-benzoyl-phenylacetamides and cyclic homologues
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
EP0144853B1 (en) * 1983-11-21 1990-09-26 Fujisawa Pharmaceutical Co., Ltd. Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
US4725619A (en) 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2216515A (en) * 1988-03-04 1989-10-11 Nippon Shinyaku Co Ltd Acylphenol derivatives
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
DE3928488A1 (de) 1989-08-29 1991-03-07 Standard Elektrik Lorenz Ag Interferometrisches messsystem
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
DE69224861T2 (de) 1991-07-30 1998-08-06 Korea Res Inst Chem Tech Neue Phenylacetamidderivate und Verfahren zu ihrer Herstellung
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5482964A (en) * 1994-10-11 1996-01-09 Warner-Lambert Company Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
KR0147963B1 (ko) 1995-01-10 1998-08-17 강박광 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US5741818A (en) * 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
AU4078897A (en) 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
AU4031697A (en) 1996-08-29 1998-03-19 Takeda Chemical Industries Ltd. Cyclic ether compounds as sodium channel modulators
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
AU734490B2 (en) 1996-11-05 2001-06-14 Neuraxon Inc. A method for treating tension-type headache
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
FR2756738B1 (fr) 1996-12-06 1999-02-12 Sod Conseils Rech Applic Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
IL119890A (en) 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
GB9706730D0 (en) 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
WO1998047869A1 (en) 1997-04-22 1998-10-29 Cocensys, Inc. Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
ATE311867T1 (de) 1997-09-08 2005-12-15 Warner Lambert Co Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
EP2201944B1 (en) * 1997-11-21 2012-05-23 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating, preventing or ameliorating manic depression
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
WO1999037296A1 (en) 1998-01-23 1999-07-29 Warner-Lambert Company Gabapentin and its derivatives for the treatment of muscular and skeletal pain
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
MXPA00007585A (es) 1998-02-04 2002-10-17 Euro Celtique Sa Semicarbazidas substituidas y el uso de las mismas.
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
PT1093366E (pt) 1998-07-09 2005-02-28 Warner Lambert Co Composicao farmaceutica que contem analogos de gaba e um agente antiviral para o tratamento de herpes zoster
US6326374B1 (en) * 1998-07-09 2001-12-04 Warner-Lambert Company Compositions comprising GABA analogs and caffeine
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
BR0009322A (pt) 1999-03-26 2002-04-30 Euro Celtique Sa Pirazóis, imidazóis, oxazóis, tiazóis e pirróis substituìdos com arila e o uso dos mesmos
EP1169060B1 (en) 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
US6310098B1 (en) 1999-07-22 2001-10-30 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
EP1297341A2 (en) 2000-06-19 2003-04-02 Merck Frosst Canada Inc. Methods of identifying gaba b? receptor subtype-specific agonists
EP1229332A3 (en) 2001-02-02 2004-07-28 Warner-Lambert Company In vitro assay for testing gabapentinoid activity
EP1423168B1 (en) 2001-09-03 2006-02-08 Newron Pharmaceuticals S.p.A. Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators

Also Published As

Publication number Publication date
AU2002333374A2 (en) 2003-03-18
ATE317280T1 (de) 2006-02-15
JP2005504782A (ja) 2005-02-17
KR100890875B1 (ko) 2009-03-31
DE60209152D1 (de) 2006-04-20
PT1423168E (pt) 2006-05-31
US8084447B2 (en) 2011-12-27
CN1556720A (zh) 2004-12-22
IL160523A (en) 2009-02-11
AU2002333374B2 (en) 2007-03-22
WO2003020273A3 (en) 2003-09-04
ES2253579T3 (es) 2006-06-01
US8710040B2 (en) 2014-04-29
NO331298B1 (no) 2011-11-21
BRPI0212298B1 (pt) 2015-11-03
MXPA04002009A (es) 2004-07-08
RU2004110041A (ru) 2005-03-10
WO2003020273A2 (en) 2003-03-13
BRPI0212298B8 (pt) 2021-05-25
SI1423168T1 (sl) 2006-06-30
DE60209152T2 (de) 2006-08-03
JP4350508B2 (ja) 2009-10-21
HK1070305A1 (en) 2005-06-17
RU2295337C2 (ru) 2007-03-20
CA2459470A1 (en) 2003-03-13
EP1423168A2 (en) 2004-06-02
CN1274306C (zh) 2006-09-13
IL160523A0 (en) 2004-07-25
CA2459470C (en) 2010-10-12
NZ531586A (en) 2005-09-30
DK1423168T3 (da) 2006-05-15
US20040248978A1 (en) 2004-12-09
NO20040907L (no) 2004-05-14
US20120142777A1 (en) 2012-06-07
KR20040034686A (ko) 2004-04-28
EP1423168B1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
BR0212298A (pt) Composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
DE50203788D1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
BRPI0410959A (pt) composição farmacêutica contendo inibidor de histona desacetilase
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0208563A (pt) composições de n-acetilcisteìna e métodos para o tratamento e prevenção de toxidade de droga
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
BR0213181A (pt) Combinações de inibidor de cox-2
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
BR0213536A (pt) Formulações de xarope de ribavirina
ES2191083T3 (es) Composicion para limpiar y/o desinfectar instrumentos para uso medico.
BR0012058A (pt) Combinação sinérgica: gabapentina e pregabalina
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
PT1368016E (pt) Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
SE0203817D0 (sv) New composition
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit
BR0108823A (pt) Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
BR0215352A (pt) Composição farmacêutica que compreende um inibidor de alfa-glicosidase e um ácido 4-oxobutanóico, e seu uso para tratar diabetes
WO2021080188A3 (ko) 단백질 발현 억제제를 포함하는 우울증의 예방 또는 치료용 조성물 및 이의 용도
BR0215498A (pt) Composição farmacêutica compreendendo uma glitazona e um ácido 4-oxobutanóico e o seu uso para o tratamento de diabetes
BR9714785A (pt) Composições desinfetantes e processos de desinfecção de superfìcies

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/16, A61K 31/165, A61K 31/195, A61K 31/197, A61K 31/445, A61K 31/4535, A61P 25/04, A61P 25/08, A61P 29/00, A61P 43/00

Ipc: A61K 31/445 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/08/2022